Latest News and Press Releases

FDA approves Longeveron's Investigational New Drug (IND) application for stem cell therapy as a potential treatment for pediatric dilated cardiomyopathy.

Than Powell appointed as Longeveron CBO to lead overall business strategy, Alzheimer's program partnering and HLHS program international strategy.

Longeveron CEO Wa’el Hashad will present at the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference.

Longeveron to host Alzheimer's disease program partnering meetings at BIO 2025 conference June 16-19. Positive Phase 2a data published in Nature Medicine.

Longeveron selected as a Semi-Finalist Team and one of the Top 40 Teams receiving a $250,000 Milestone 1 Award in the XPRIZE Healthspan competition.

Longeveron announces Q1 2025 financial results & provides business update. Pivotal Phase 2 clinical trial achieves 95% enrollment. Expected full enroll Q2.

Longeveron issues letter to shareholders highlighting corporate strategy, recent progress and 2025 key priorities and goals.

Dublin, March 18, 2025 (GLOBE NEWSWIRE) -- The "Stem Cell Therapy Market by Therapy Type (Allogeneic Therapy, Autologous Therapy), Cell Source (Adult Stem Cells, Embryonic Stem Cells, Induced...

Longeveron positive Phase 2 clinical trial data in Alzheimer's disease published in peer reviewed journal Nature Medicine.

Dublin, March 07, 2025 (GLOBE NEWSWIRE) -- The "Animal Stem Cell Therapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F" report has been added to ...